-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In Pfizer's second-quarter 2020 earnings conference call last week, analysts turned more attention to the company's possible future returns from the development of the new crown vaccine, so much so that biosypolysed drugs, the business area that is now making gains, were neglected.
, global sales of Pfizer Biosynthics rose 36 percent to $289 million.
, an analyst at Bernstein, a top U.S. financial advisory firm, said in a note to investors earlier this week that Pfizer and Amven were involved in the "golden age" of the U.S. biosychical drug industry.
In February 2020, Pfizer became the first company on the U.S. market to sell three monoclonal antibody biosynthic drugs, all of which are "discounted" versions of Roche's cancer star products: Zirabev, Ruxience and Trazimera.
22-24 per cent off the original drugs compared to the original drugs.
conference call, Pfizer Chief Executive Albert Boura cited strong "early results" for the three products, particularly outside the U.S. market, with strong demand from Trazimera.
investors should not underestimate the potential of the U.S. biosynthic drug market.
To prove it, Gal analyzed data from Pfizer's biosynthic drug Inflectra, which accounts for only 10 per cent of the US market and 30 per cent of the price-sensitive European market.
because of Inflectra's higher prices in the U.S., revenues in both markets are impressive, with sales of $158 million in the U.S. and $116 million in Europe in the second quarter.
Gal predicts annual sales of $2.1 billion for Pfizer's bio-similar drug business, which will eventually bring in nearly $3 billion a year.
same time, Amjin's biosypolyte business is climbing, with Gal estimating revenue of $357 million in the second quarter of this year, or $1.4 billion on an annual basis.
is dominating the U.S. biosychables market, including the Herceptin biosychable Kanjinti, which is partnered with Aer Jian, which holds a 32 percent commercial share, and Avastin's biosynthic drug Mvasi, which also has a 39 percent share.
Gal said the addition of Remicade's biosynthics to its drug business and the launch of Rituxan biosynthics later this year should bring the company's revenue in the sector to $2 billion.
"I think suppliers are looking for more markets where bioso-like drugs can get more value in the health care system."
" Gordon said: "We have less challenges in terms of share, but the entry of multiple competitors will bring some changes to net prices.
" Gal admits: "Price pressures will not soon end the golden age of bioso-like drugs."
the entire biosypolysed drug system is increasing, there will be a transition in the drug model that should not come before the middle of this decade.
"